Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DRM02 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| DRM02 | EXPERIMENTAL | DRM02 Topical Gel, 0.25% |
| Vehicle | PLACEBO_COMPARATOR | DRM02 Topical Gel, Vehicle |
| Name | Type | Description |
|---|---|---|
| DRM02 | DRUG | - |
| Vehicle | OTHER | - |
Inclusion Criteria: * Male or female 18 to 70 years of age. * Plaque-type psoriasis with two lesions of similar size and have an identical score of at least 6 but no more than 8 on the sum of the individual components of the Severity of Psoriasis Area Severity Index (PASI) at the Target Lesion scal...
DRM02 is an investigational small molecule being studied for the treatment of plaque psoriasis and rosacea. It is in Phase 2 clinical development for these dermatological conditions. The drug is being developed by Eli Lilly and Company.
DRM02 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. The drug is currently in Phase 2 clinical trials for psoriasis and rosacea.
DRM02 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in plaque psoriasis and one in rosacea. The drug is investigational and has not been approved by regulatory authorities.
DRM02 has completed two Phase 2 clinical trials. NCT01993433 studied the drug in subjects with plaque psoriasis, and NCT01993446 studied it in subjects with rosacea. Both trials were completed in Canada and enrolled adults aged 18 years and older.
DRM02 is the name used in clinical trials for this investigational small molecule. No alternative names have been reported for this drug in the available clinical trial information.